Back to discover

Protein / target

Tyrosine-protein kinase Lyn

Encoded byLYNP07948Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
2
Approved medicines
Open Targets target-level
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Non-membrane spanning protein tyrosine kinase

Strongest disease association

Autoinflammatory disease, systemic, with vasculitis

Via encoding gene LYN · Genetic evidence · score 0.85

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic…

View complete UniProt function annotation

Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending on the context. Required for the initiation of the B-cell response, but also for its down-regulation and termination. Plays an important role in the regulation of B-cell differentiation, proliferation, survival and apoptosis, and is important for immune self-tolerance. Acts downstream of several immune receptors, including the B-cell receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. Plays a role in the inflammatory response to bacterial lipopolysaccharide. Mediates the responses to cytokines and growth factors in hematopoietic progenitors, platelets, erythrocytes, and in mature myeloid cells, such as dendritic cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an important role in integrin signaling. Regulates cell proliferation, survival, differentiation, migration, adhesion, degranulation, and cytokine release. Involved in the regulation of endothelial activation, neutrophil adhesion and transendothelial migration (PubMed:36932076). Down-regulates signaling pathways by phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then serve as binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases and their substrates. Phosphorylates LIME1 in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL fusion protein. Required for rapid phosphorylation of FER in response to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector of EPOR (erythropoietin receptor) in controlling KIT expression and may play a role in erythroid differentiation during the switch between proliferation and maturation. Depending on the context, activates or inhibits several signaling cascades. Regulates phosphatidylinositol 3-kinase activity and AKT1 activation. Regulates activation of the MAP kinase signaling cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Phosphorylates SCIMP on 'Tyr-107'; this enhances binding of SCIMP to TLR4, promoting the phosphorylation of TLR4, and a selective cytokine response to lipopolysaccharide in macrophages (By similarity). Phosphorylates CLNK (By similarity). Phosphorylates BCAR1/CAS and NEDD9/HEF1 (PubMed:9020138)

Subcellular location

Cell membraneNucleusCytoplasmCytoplasm, perinuclear regionGolgi apparatusMembrane
Domains and Gene Ontology detail (121)

Domains & features

SH3SH2Protein kinase

Gene Ontology

  • Cadherens junction
  • Ccytoplasm
  • Ccytoplasmic side of plasma membrane
  • Ccytosol
  • Cendocytic vesicle membrane
  • Cextracellular exosome
  • Cglutamatergic synapse
  • CGolgi apparatus
  • Cintegrin alpha2-beta1 complex
  • Clysosomal membrane
  • Cmembrane raft
  • Cmitochondrial crista

512 aa · 59 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOCell migrationGOLipid & lipoprotein metabolismGOReceptor tyrosine kinase signallingGOHaemostasisUniProt · GO · ReactomeImmune signallingUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·negative regulation of cell population proliferation
  • ·positive regulation of cell population proliferation

Cell migration

  • ·positive regulation of cell migration
  • ·regulation of monocyte chemotaxis

Lipid & lipoprotein metabolism

  • ·fatty acid transport
  • ·response to sterol depletion

Receptor tyrosine kinase signalling

  • ·cell surface receptor protein tyrosine kinase signaling pathway

Haemostasis

  • ·Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors…
  • ·platelet degranulation
  • ·regulation of platelet aggregation
  • ·Platelet Adhesion to exposed collagen

Immune signalling

  • ·Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors…
  • ·adaptive immune response
  • ·B cell homeostasis
  • ·B cell proliferation
View underlying pathways (25)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

CD79ASYKBLNKCD19GP6BTKCD79BFYNVAV1SHC1LYN

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

bosutinib
ApprovedInhibitor

Tyrosine-protein kinase Lyn inhibitor

Direct interaction with this protein · 1 of 4 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene LYN

Gene-level evidence surfaced through the gene LYNthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Autoinflammatory disease, systemic, with vasculitis
0.88Well supported

Genetic evidence dominant · Open Targets 0.71

Neoplasms
0.83Well supported

Clinical evidence dominant · Open Targets 0.57

chronic myelogenous leukemia, BCR-ABL1 positive
0.78Well supported

Clinical evidence dominant · Open Targets 0.60

Precursor Cell Lymphoblastic Leukemia-Lymphoma
0.70Moderately supported

Clinical evidence dominant · Open Targets 0.56

Breast Neoplasms
0.57Moderately supported

Clinical evidence dominant · Open Targets 0.44

View evidence synthesis (5)
Autoinflammatory disease, systemic, with vasculitisWell supported
0.88
agreement 0.751.00
Genetic84%Animal model17%Genetic literaturedup

Open Targets aggregate 0.71 · 2 independent evidence families · 1 not counted as duplicate

NeoplasmsWell supported
0.83
agreement 0.740.92
Clinical42%Pathway27%Genetic14%Literature10%Somatic mutation7%

Open Targets aggregate 0.57 · 5 independent evidence families

chronic myelogenous leukemia, BCR-ABL1 positiveWell supported
0.78
agreement 0.650.91
Clinical76%Animal model20%Literature4%

Open Targets aggregate 0.60 · 3 independent evidence families

Precursor Cell Lymphoblastic Leukemia-LymphomaModerately supported
0.70
agreement 0.550.86
Clinical87%Literature13%

Open Targets aggregate 0.56 · 2 independent evidence families

Breast NeoplasmsModerately supported
0.57
agreement 0.410.72
Clinical81%Literature19%

Open Targets aggregate 0.44 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Autoinflammatory disease, systemic, with vasculitis0.71
chronic myelogenous leukemia, BCR-ABL1 positive0.60
Neoplasms0.57
Precursor Cell Lymphoblastic Leukemia-Lymphoma0.56
Neurodegenerative Diseases0.53
Leishmaniasis, Cutaneous0.46
Breast Neoplasms0.44
Leukemia, Lymphoid0.41
Dengue0.37

Drug development

9 compounds recorded · 2 approved · 7 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (9)
JNJ-26483327Phase 1
TOLIMIDONEPhase 2
DASATINIB ANHYDROUSApproval
ILORASERTIBPhase 2
BAFETINIBPhase 2
XL-228Phase 1
ENMD-981693Phase 2
BOSUTINIBApproval
TG100-801Phase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (13)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confAB · Human Protein Atlas locPR · LiteraturePR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

regulation of catalytic activityToxCast

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

4

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2026-06-12

    Approval: BOSUTINIB (ANDA209624)

    fda · regulatory · fda · via bosutinib

  2. Regulatory approval2025-05-23

    Approval: BOSUTINIB (ANDA209543)

    fda · regulatory · fda · via bosutinib

  3. New publication2020-03-03
    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Leukemia · 2020 · 1,035 citations · Europe PMC · via bosutinib

  4. Regulatory approval2013-03-27

    Approval: Bosulif (EMA)

    ema · regulatory · ema · via bosutinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.